Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, or corticosteroid-free remission in patients with active luminal crohn's disease - Université de Lille Accéder directement au contenu
Article Dans Une Revue Gastroenterology Année : 2018

Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, or corticosteroid-free remission in patients with active luminal crohn's disease

Geert d''Haens
  • Fonction : Auteur
Severine Vermeire
  • Fonction : Auteur
Guy Lambrecht
  • Fonction : Auteur
Filip Baert
  • Fonction : Auteur
Peter Bossuyt
  • Fonction : Auteur
Anthony Buisson
  • Fonction : Auteur
Yoram Bouhnik
Jerome Filippi
  • Fonction : Auteur
C. Janneke van der Woude
  • Fonction : Auteur
Philippe van Hootegem
  • Fonction : Auteur
Jacques Moreau
  • Fonction : Auteur
Edouard Louis
  • Fonction : Auteur
Denis Franchimont
  • Fonction : Auteur
Martine Devos
  • Fonction : Auteur
Fazia Mana
  • Fonction : Auteur
Laurent Peyrin-Biroulet
  • Fonction : Auteur
Hedia Brixi
  • Fonction : Auteur
Matthieu Allez
  • Fonction : Auteur
Philip Caenepeel
  • Fonction : Auteur
Alexandre Aubourg
  • Fonction : Auteur
Bas Oldenburg
  • Fonction : Auteur
Marieke Pierik
  • Fonction : Auteur
Ann Gils
  • Fonction : Auteur
Sylvie Chevret
  • Fonction : Auteur
David Laharie
  • Fonction : Auteur

Résumé

A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a prospective, randomized trial to determine whether therapeutic drug monitoring (TDM) to maintain serum levels of infliximab above 3 μg/mL produced higher rates of clinical and endoscopic remission than adapting dose based only on symptoms. We performed a double-blind trial in which 122 biologic-naïve adult patients with active CD (71 female, median age 29.8 years) received induction treatment with infliximab in combination with an immunosuppressant, from July 2012 through September 2015 at 27 centers in Europe. At week 14 of treatment, patients were randomly assigned (1:1:1) to 3 infliximab maintenance groups: dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (dose intensification strategy [DIS]1 group); dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group); dose increase to 10 mg/kg based on clinical symptoms alone (controls). Patients' CD activity index scores, levels of C-reactive protein, fecal levels of calprotectin, and serum concentrations of infliximab were determined at baseline and at weeks 2, 4, 6, 12, and 14 of treatment, and then every 4 weeks thereafter until week 54. The primary endpoint was sustained corticosteroid-free clinical remission (CD activity index <150) from weeks 22 through 54 with no ulcers at week 54. The primary endpoint was reached by 15 (33%) of 45 patients in the DIS1 group, 10 (27%) of 37 patients in the DIS2 group, and 16 (40%) of 40 patients in the control group (P = .50). In a prospective randomized exploratory trial of patients with active CD, we found increasing dose of infliximab based on a combination of symptoms, biomarkers, and serum drug concentrations does not lead to corticosteroid-free clinical remission in a larger proportion of patients than increasing dose based on symptoms alone. 2011-003038-14.

Dates et versions

hal-04429655 , version 1 (31-01-2024)

Identifiants

Citer

Geert d''Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, et al.. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, or corticosteroid-free remission in patients with active luminal crohn's disease. Gastroenterology, 2018, Gastroenterology, 154, pp.1343-1351. ⟨10.1053/j.gastro.2018.01.004⟩. ⟨hal-04429655⟩

Collections

RIIP UNIV-LILLE
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More